Aradigm, Novo Nordisk deal

ARDM granted partner NVO full development and manufacturing rights to the AERx insulin Diabetes Management System (iDMS). Under the deal, NVO will pay $55 million in cash for the manufacturing equipment and leasehold improvements used by ARDM. NVO also will assume responsibility for further development of AERx iDMS (NN1998), which is in Phase III testing. ARDM is eligible for royalties.

Under a 1998 deal, NVO had exclusive worldwide marketing rights, and ARDM was to manufacture AERx systems in exchange for a share of the gross profits on NVO's sales (see BioCentury, June 8, 1998). ...